RTX in ANCA-Associated Vasculitis: Summary to Date
{"Image DocumentName": "RTX in ANCA-Associated Vasculitis: Summary to Date", "Image ImageDescription": "In ANCA-associated vasculitis, most but not all preliminary (noncontrolled) studies of B-cell depletion suggest that this strategy is a safe and effective mechanism-based approach for remission induction and maintenance. Repeated courses are equally effective and thus far associated with few infectious complications. Limited trials in cryoglobulinemia with and without HCV infection have demonstrated efficacy and reasonable safety of anti-CD20 based therapy. A large controlled trial of RTX for ANCA-associated vasculitis (RAVE) is fully recruited and analysis is pending (www.clinicaltrials.gov) HCV, hepatitis C virus.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}